A single case study was used to examine two middle grades mathematics teachers' use of short-cycle formative assessment strategies. Data was collected using multiple sources to provide a description of this single case. Participant change in knowledge of short-cycle formative assessment strategies was collected and analyzed through participant pre- and post-interviews and targeted instructional support was provided through professional development sessions designed to meet diverse needs of participants. Participant change in use of short-cycle formative assessment strategies was collected and analyzed through classroom observations using Assess Today observation protocol and targeted instructional support was provided through post-observation conferences with written feedback. Findings from the study verified that changes in teachers' use of short-cycle formative assessment strategies were positively influenced by the targeted instructional support provided to each participant during the study. The study further indicated that an assessment of teacher's present knowledge and use of short-cycle formative assessment strategies should be considered before providing targeted instructional support to maximize the learning potential for each teacher. Future research is needed regarding the importance of building student self-efficacy through teacher use of short-cycle formative assessment, as well as the importance of involving students in the formative assessment process.

A key to a business's success is reaching the target market. This ensures that consumers are exposed to the retailer's offerings and by turn, inspired to purchase. In turn, the business can reach its goal of a profitable organization. The purpose of this paper was to determine the most effective fashion advertising appeals for reaching target markets. To address these issues, this thesis consisted of two studies. The purpose of the first study was to determine the advice given to fashion entrepreneurs regarding effective target market practices. The purpose of the second study was to determine effective advertising strategies fashion entrepreneurs may employ for effectively reaching target markets. Data was collected to test the effectiveness of the advice from Study 1, degrees of brand awareness, attitudes towards advertising, willingness to follow trends, purchase intention, purchase behavior, and shopping involvement. The Theory of Reasoned Action was employed as the theoretical framework of the study. The framework was utilized to predict that attitudes towards targeted advertising and pressure to follow fashion trends would positively relate to intent to purchase which, in turn, would positively relate to purchase behavior. The results of this paper concluded the TRA model provided a proper framework to predict purchase behavior from targeted advertising employed by fashion entrepreneurs.

Im Vergleich zu anderen Krebsentitäten, konnten Patienten mit PDAC bisher kaum von Therapieerfolgen der Präzisionsmedizin profitieren. Um diese Problematik zu adressieren, habe ich eine umfassende molekularbiologische Studie durchgeführt, um prädiktive Biomarker zu identifizieren und die Risikostratifizierung der Patienten zu verfeinern. Mittels gen-spezifischer Sequenzierung und gezielter RNA-Expressionsanalyse wurden 293 R0-resezierte Patienten aus einer multizentrischen Phase-III-Studie untersucht. Ziel der klinischen Studie war der Vergleich von adjuvanter Chemotherapie mit Gemcitabin entweder mit oder ohne Zusatz von Erlotinib. Für meine Arbeit wurden die Patientenproben unter Verwendung einer nicht-negativen Matrixfaktorisierung (NMF) basierend auf ihren Einzelnukleotidvarianten (SNV) und ihren Kopienzahlveränderungen (CNA) gruppiert und auf klinische und molekularbiologische Unterschiede untersucht. Um die biologischen Hintergründe der identifizierten genetischen Besonderheiten zu verstehen, wurden anschließend Zelllinien genetisch modifiziert und in vitro modelliert. Es wurden 1086 SNVs und 4157 CNAs identifiziert. Dabei wiesen 99% aller Patienten mindestens eine genetische Veränderung auf, mit durchschnittlich 18 Aberrationen pro Patient. In Übereinstimmung mit früheren Berichten waren KRAS, TP53, CDKN2A und SMAD4 die am häufigsten betroffenen Gene. Alterationen in diesen Genen konnten in 63-93 % der Fälle nachgewiesen werden. Basierend darauf konnte ich fünf Patientengruppen identifizieren die sich in ihren biologischen Charakteristika unterscheiden und Angriffspunkte für gezielte Therapien bieten. Mittels NMF wurden zudem SMAD4alt MAPK9low als prognostische Biomarker für Erlotinib identifiziert. Anschließende in vitro Experimente zeigten, dass dies nicht auf eine Erhöhung der Erlotinib-Zelltoxizität zurückzuführen ist. Zuletzt definiere ich einen prognostischen Score der genutzt werden kann um das Überleben von R0-resizierten PDAC Patienten abzuschätzen. / In contrast to other cancer entities, PDAC patients have not benefited from recent improvements in precision medicine. To address this gap, I embarked on a comprehensive molecular study to identify predictive biomarkers and refine risk stratification. I performed targeted sequencing and targeted RNA expression analysis of 293 R0-resected patients from a multicenter phase III trial comparing adjuvant chemotherapy of gemcitabine with or without erlotinib. Patients were clustered using non-negative matrix factorization (NMF) based on their single nucleotide variant (SNV) and copy number alteration (CNA) statuses. Overall (OS) and disease-free survival (DFS) were analysed with the multivariate cox hazard and log rank tests. Finally, using a method based on CRISPR/Cas, findings from the patient cohort where modeled in vitro to assess their biological backgrounds. A total of 1,086 SNVs and 4,157 CNAs were found with at least one genetic alteration in 99% of all patients, and an average of 18 aberrations per patient. In line with previous reports, KRAS, TP53, CDKN2A, and SMAD4 were the most frequently affected genes, detected in 63–93 % of cases. In this thesis, I identified five biologically distinct patient subgroups with different actionable lesions that may serve for refined PDAC classification and tailored treatment approaches. NMF based clustering and subsequent differential expression analysis revealed SMAD4alt (SNV and/or CAN in SMAD4) MAPK9low (MAPK9 expression below median) as prognostic erlotinib biomarker. Modeling of SMAD4alt MAPK9low status in vitro showed that the effect is not based on increased erlotinib toxicity. Finally, I proposed a genetic risk score for prognostic evaluation of newly diagnosed R0-resected PDAC patients.

Das Glykoprotein A33 (GPA33) ist ein aussichtsreiches Antigen für eine zielgerichtete Therapie, da es vorwiegend in Darmepithelien und Darmkrebs vorkommt. Klinische Studien zu GPA33-gerichteten Antikörpertherapien haben aber festgelegte Ansprechraten nicht erreicht. Zur Untersuchung der geringen Wirksamkeit und Verbesserung der Therapien habe ich GPA33-Expression in Darmkrebs untersucht, mit GPA33-Regulation interferiert und eine zelluläre GPA33-gerichtete Therapiealternative entwickelt. Mithilfe von Immunhistochemie und Immunfluoreszenz in zwei Kolorektalkarzinom-Kohorten entdeckte ich Heterogenität in der GPA33-Expression. Ich fand eine inverse Korrelation zwischen hoher GPA33-Expression und Metastasierung sowie einen konsistenten GPA33-Expressionsphänotyp im Primärtumor und Fernmetastasen. GPA33-positive Zellen waren zentral lokalisiert und hatten geringe WNT-Aktivität. GPA33-negative Zellen an der invasiven Front wiesen erhöhte WNT-Aktivität auf. Zur Untersuchung der Verbindung zwischen Zellsignalwegen und GPA33-Expression griff ich in onkogene Signalwege und Transkriptionsfaktoren ein. Meine Ergebnisse zeigten eine CDX1-abhängige transkriptionelle Regulierung der GPA33-Expression und eine inverse Korrelation mit dem WNT-Signalweg in vitro. Die Herunterregulierung der WNT-Aktivität erhöhte GPA33-Expression in vitro und in GPA33-negativen Tumorzellsubpopulationen in Xenotransplantaten. Schließlich entwickelte ich GPA33-CAR-T-Zellen und untersuchte ihre Anti-Tumor-Aktivität. GPA33-CAR T-Zellen wurden als Reaktion auf GPA33-positive Darmkrebszellen aktiviert und reduzierten das Tumorwachstum in Mäusen. Zusammenfassend identifiziert diese Studie intratumorale Heterogenität als Ursache für die geringe Wirksamkeit GPA33-gerichteter Therapie und zeigt, dass diese Therapie durch WNT-Inhibition verbessert werden könnte. Zudem liefere ich präklinische Beweise für den Einsatz einer GPA33-gerichteten Immuntherapie gegen Darmkrebs. / The cell surface Glycoprotein A33 (GPA33) is a promising antigen for targeted therapy, predominantly expressed in intestinal epithelia and colorectal cancer. Prior clinical trials with GPA33-targeted antibodies have not achieved desired response rates. To investigate low efficacy and improve therapies, I explored GPA33 expression, interfered with GPA33-regulatory mechanisms, and developed a cellular GPA33-targeted therapy alternative. Using immunohistochemistry and immunofluorescence on two colorectal cancer cohorts, I discovered heterogeneity in GPA33 expression. I found an inverse correlation of high GPA33 expression with progressive disease and consistent GPA33 expression in primary tumor and distant metastasis. GPA33-positive cells were centrally localized with low WNT activity, whereas GPA33-negative cells were at the invasive front with elevated WNT signaling. To understand the functional link between cell signaling networks and GPA33 expression, I interfered with oncogenic signaling pathways and transcription factors. My findings revealed CDX1-dependent transcriptional regulation of GPA33 and an inverse correlation with WNT signaling in vitro. Downregulation of WNT activity increased GPA33 expression in vitro and in GPA33-negative tumor cell subpopulations in subcutaneous xenograft models. Finally, I developed GPA33-CAR T cells and assessed their anti-tumor activity using flow cytometry, ELISA, live-cell imaging, and adoptive transfer. GPA33-CAR T cells were activated in response to GPA33-positive colorectal cancer cells and reduced xenograft growth in tumor-bearing mice. In conclusion, this study identifies intratumoral heterogeneity as a potential cause for low treatment efficacy and demonstrates that GPA33-targeted therapy could be enhanced by simultaneous WNT inhibition to boost GPA33 expression in colorectal cancer cells. Additionally, I provide preclinical evidence supporting the use of cellular immunotherapy to target GPA33 in colorectal cancer.

Preface: The research about product development of a prosthetic socket was conducted by two students from Mälardalen University, department of Innovation, Design, and Technology. Background: The most recent public survey shows that an estimated 5 million people in China are amputees, out of which a significantly large portion are below-elbow amputees. Sockets sold to below-elbow amputees are equipped with only two surface electromyography sensors, has low comfortability, has problems with perspiration, and a high weight. The current standard for socket manufacturing has not changed in decades. Research Questions: The following research questions have determined the direction of the research: (1) What measurable factors contribute to a convenient and ergonomic feature design in prosthetic socket from the end-user’s perspective? (2) How can the weight and functionality be improved to achieve a prosthetic socket more suited to the end-user, with respect to the existing prosthetic socket? (3) Which material and manufacturing method is suitable for producing cost-effective and customized prosthetic sockets? Research Method: The research was guided by the 5th edition of Product Design and Development by Ulrich & Eppinger (2012) where the product development process described in five of the six phases from planning to test and refinement were utilized. The data collection and analysis techniques performed in this research was guided by Research Methods for Students, Academics and Professionals by Williamson & Bow (2002). Interviews were conducted with five different stakeholders to find specifications of requirements and concretize subjectivism of what defines quality and ergonomics. Implementation: Currently, below-elbow amputees order sockets from orthopedic clinics. The socket was identified as a product of Ottobock. Investigations were made to find optimal solutions to the specification of requirements. Results: The development of a socket concept was designed for additive manufacturing using a multi-jet fusion printer. Analysis: This concept had significant improvements to parameters: higher grade of customizability, 30 % reduced weight, 48 % cost reduction, a new production workflow with 93,5 % automation, and a 69 % reduction in manual work hours. Conclusions: The data of the research strongly indicate existing potentials in enhancing socket design techniques and outputs by implementation of additive manufacturing processes. This can prove to be beneficial for achieving more competitive prosthetics and associated services. / Förord: Denna forskning om produktutvecklingsprocessen av en armprotes genomfördes av två studenter från Mälardalens universitet, avdelningen för innovation, design och teknik. Bakgrund: Den senaste offentliga undersökningen visar att cirka 5 miljoner människor i Kina är amputerade, varav en betydligt stor del är under-armbågsamputerade. Armproteser som säljs till underarmsamputerade individer är utrustade med endast två yt-elektromyografiska sensorer, har låg komfort, har problem med perspiration och hög vikt. Den nuvarande standarden för armproteser har inte förändrats under årtionden. Forskningsfrågor: Följande forskningsfrågor har bestämt riktningen för forskningen: (1) Vilka mätbara faktorer bidrar till en praktisk och ergonomisk funktionsdesign i underarmsproteser ur slutanvändarens perspektiv? (2) Hur kan vikten och funktionaliteten förbättras för att åstadkomma en underarmsprotes som är bättre anpassad för slutanvändaren med avseende på den befintliga underarmsprotesen? (3) Vilket material och tillverkningsmetod är lämpligt för att producera kostnadseffektiva och anpassade underarmsproteser? Forskningsmetod: Forskningsmetoden styrdes av den femte upplagan av Product Design and Development av Ulrich & Eppinger (2012) där produktutvecklingsprocessen är uppdelad i sex faser. I denna forskning användes de fem första faserna från planering till testning och justering. Tekniker för datainsamling och analys som användes i denna forskning styrdes av Research Methods for Students, Academics and Professionals av Williamson & Bow (2002). Intervjuer genomfördes med fem olika intressenter för att hitta kravspecifikationer och för att konkretisera subjektivitet för vad som definierar kvalitet och ergonomi. Implementering:  Underarmsamputerade individer beställer för närvarande armproteser från ortopediska kliniker. Armprotesen identifierades som en produkt av Ottobock. Undersökningar gjordes för att hitta optimala lösningar för kravspecifikationen. Resultat: Konceptutvecklingen av en armprotes utformades för additiv tillverkning med hjälp av en multi-jet-fusion-skrivare. Analys: Det här konceptet hade betydande förbättringar av parametrar: högre grad av anpassningsbarhet, 30 % minskad vikt, 48 % kostnadsreduktion, ett nytt produktionsflöde med 93,5 % automatisering och en 69 % minskning av manuella arbetstider. Slutsatser: Data från denna forskning indikerar att det finns starkt potential för att förbättra designtekniker och utgångar av underarmsproteser genom implementering av additiva tillverkningsprocesser. Detta kan visa sig vara fördelaktigt för att uppnå mer konkurrenskraftiga proteser och tillhörande tjänster.

Oral squamous cell carcinoma (OSCC) is the most common head and neck cancer, with a worldwide incidence of 275,000 new cases annually (Warnakulasuriya, 2009). Globally, the head and neck carcinoma represents a major cause of morbidity and mortality and is the sixth most commonly occurring cancer (Warnakulasuriya, 2009). A majority (>90%) of the head and neck cancers are squamous in origin and thus are linguistically referred to as head and neck squamous cell carcinoma (HNSCC) (Warnakulasuriya, 2009). HNSCC includes cancers of the oral cavity, larynx and pharynx; oral cancer being the most common (Warnakulasuriya, 2009). Although, HNSCC is the sixth most common cancer globally (Warnakulasuriya, 2009), the Indian scenario is graver. According to GLOBOCAN 2008 (http://globocan.iarc.fr), the worldwide age standardized incidence rate (ASR) for HNSCC (and thus OSCC) is 5.3 and 2.5 per 100,000 males and females respectively (Ferlay et al., 2010). In India, the ASR is 9.8 and 5.2 per 100,000 males and females respectively, clearly demonstrating a remarkably high incidence rate of OSCC (Ferlay et al., 2010; http://globocan.iarc.fr). OSCC is a peculiar cancer which is largely preventable and rarely presents as a familial disorder. The most common etiological factors associated with OSCC include tobacco and alcohol consumption (Johnson, 2001). Additionally, high risk human papillomaviruses (HPV strains 16 and 18) as well as genetic predispositions have been implicated. The treatment of OSCC mainly relies on surgical resection of the tumor. The site, size, depth of infiltration and proximity to the bone of the tumor determine whether a combination of surgery with radiation therapy or chemotherapy would be advised (Scully and Bagan, 2009). The concomitant chemo-radiation therapy is the most commonly used strategy in locally advanced cancer. Taxanes (e.g., paclitaxel and docetaxel) and platinum-based induction chemotherapy (e.g., cisplatin) are the options in the treatment of locally advanced cancer. Epidermal growth factor receptor (EGFR) targeted with cetuximab in combination with radiotherapy has been successfully tested in a large randomized trial and thus is currently a new option (Scully and Bagan, 2009). The success of cetuximab has paved the path for the development and implementation of molecules targeting various signaling pathways. Despite extensive research on oral squamous cell carcinoma (OSCC), the five-year survival rate has not changed in several decades with the exception of the targeted treatment strategies involving cetuximab as discussed above. The current chemotherapeutic approaches lack selectivity and are flagitious. Thus, effective treatment of OSCC requires the identification of molecular targets to design appropriate therapeutic strategies. To this end, the present study took three distinct approaches in order to validate the use of existing targets and to reveal novel prognostic biomarkers and therapeutic targets. 1) Targeting the PI3K-AKT-MTOR pathway in OSCC and identification of determinants of its sensitivity. 2) Gene expression analysis of ectopically overexpressed TSC2 to identify new therapeutic targets and prognostic biomarkers as well as to elucidate the genes regulated by it. 3) Expression profiling of CYP1B1 in order to validate the use of CYP1B1 based prodrug therapy in OSCC. Investigations pertaining to the changes in gene and protein expression profiles in malignant as well as pre-malignant lesions have documented the deregulation of the PI3K-AKT-MTOR (phosphoinositide 3-kinase-AKT-mechanistic target of rapamycin) and EGFR (epidermal growth factor receptor) pathways in OSCC which are being widely targeted in many therapeutic strategies (Molinolo et al., 2007; Chakraborty et al., 2008; Matta and Ralhan, 2009; Molinolo et al., 2009; Stransky et al., 2011). The PI3K-AKT-MTOR pathway is a central hub for controlling cellular proliferation and growth in response to various intracellular as well as extracellular stimuli. Crucial signaling cascades including WNT, RAS, HIF-1α and AMPK cross-talk with the PI3K-AKT-MTOR pathway at a variety of molecular junctions. Thus, making this pathway sensitive to perceiving various growth modulatory conditions, ranging from the presence of growth factors to hypoxia and nutrient deprivation (Sengupta et al., 2010; Yang and Guan, 2007). The aberrant expression of the PI3K-AKT-MTOR pathway in OSCC advocated the targeting of this coveted pathway (Chakraborty et al., 2008). In various cancers, the monotherapeutic treatments with inhibitors like LY294002 (PI3K inhibitor) and rapamycin (MTOR inhibitor) demonstrated reduced efficacies. Such reduced efficacies were attributed to the drug toxicity and non-specific action of LY294002 (Davies et al., 2000; Sun et al., 2005; Ikezoe et al., 2007; Wang et al., 2008; Liu et al., 2009), or the ablation of a feedback inhibition loop leading to the reactivation of the PI3K-AKT-MTOR pathway by rapamycin (O'Reilly et al., 2006; Carracedo et al., 2008). Thus, rapamycin or its analogues demonstrated mediocre efficacy due to cytostatic effects in clinical trials, primarily due to the paradoxical activation of major survival kinases namely MAPK and AKT (O'Reilly et al., 2006; Carracedo et al., 2008). The present study aimed at increasing the efficacy of these drugs by incorporating a combinatorial approach. The MTT assay demonstrated that prolonged monotherapeutic treatments with rapamycin led to a modest growth inhibition in three OSCC (KB, SCC131 and SCC084) and HeLa cell lines. Western blot analysis of the phosphorylation status of AKT and RPS6KB1 revealed that monotherapeutic treatments with rapamycin for 96 hr led to the reactivation of the PI3K-AKT-MTOR pathway. Thus, the modest growth inhibitory effect of rapamycin was attributed to the reactivation of the PI3K-AKT-MTOR pathway. A combinatorial treatment approach was hence believed to circumvent this problem in order to increase the efficacy of targeting the PI3K-AKT-MTOR pathway. The PI3K inhibitor LY294002 was used combinatorially with rapamycin. This prolonged dual combinatorial treatment regime was distinctly more efficacious than either of the drugs alone and led to a reduction in cellular viability accompanied by increased sub-G1 population, indicating marked cell death that was characterized as caspase-3 dependent apoptosis. The differential sensitivity of the cell lines towards this combinatorial treatment revealed a novel determinant of the sensitivity, the transactivation of EGFR. The cell lines (SCC131 and SCC084) that were capable of transactivating EGFR were relatively resistant to the dual targeting of PI3K and MTOR in comparison to cell lines that did not transactivate EGFR (HeLa and KB). Further, targeting PI3K, MTOR and EGFR simultaneously was more efficacious in the presence of EGFR transactivation than dually targeting PI3K and MTOR. The results conclusively proved that the combinatorial therapeutic approach dually targeting PI3K and MTOR is a promising treatment strategy as compared to a monotherapeutic treatment and a major factor determining the sensitivity towards this treatment is the status of autophosphorylation of EGFR (Tyr1173) which governs the potential for EGFR transactivation by the combinatorial treatment. Thus, this study demonstrated that the status of EGFR autophosphorylation (Tyr1173) can be used as a biomarker to predict the sensitivity towards the combinatorial targeting of PI3K and MTOR in OSCC. The PI3K-AKT-MTOR pathway is negatively regulated by TSC2 (tuberous sclerosis complex 2; tuberin) (Tee et al., 2002). The importance of the TSC2 gene in the regulation of cell growth and proliferation is irrefutable. TSC2 facilitates the crosstalk between a variety of cellular signals, making it a crucial hub where many cellular networks integrate like AKT, MAPK and AMPK (Clements et al., 2007; Rosner et al., 2007; Rosner et al., 2008). It is a tumor suppressor gene and is downregulated in many cancers including OSCC (Chakraborty et al., 2008). In order to identify the genes regulated by TSC2 in OSCC, we stably overexpressed TSC2 in KB cells and the changes in the gene expression profiles caused by this ectopic overexpression were observed using a whole genome expression microarray. The results showed differential regulation of 268 genes (107 genes were upregulated and 161 genes were downregulated, p<0.05, fold change ≥ 1.5). A majority of these genes were functionally associated with transcription, cell growth and proliferation, apoptosis, cell cycle and neurogenesis. Functional annotation and network analysis was performed by using the DAVID v6.7 and IPA version 8.7 softwares. The microarray data revealed a novel aspect in the crosstalk between WNT signaling and TSC2, namely the transcriptional regulation of WNT signaling by TSC2. Further, in the context of therapeutic applications, the microarray analysis revealed multiple genes that were functionally categorized to be involved in response to radiation, UV and drugs (e.g., SERPINB13 and IL1B). Future studies on the regulation of such genes that are involved in responses to drugs and radiation may give insights into the role of TSC2 in resistance or sensitivity towards chemotherapy and radiation therapy. Moreover, EREG, a member of the epidermal growth factor family, was found to be the most downregulated gene in the microarray analysis. Previous reports have documented elevated levels of EREG in tuberous sclerosis lesions and its association with poor clinical prognosis in OSCC patients (Li et al., 2008; Shigeishi et al., 2008), making its regulatory aspects intriguing. Additionally, published data on the transcriptional functions of TSC2 instigated us to analyze the role of TSC2 in the regulation of EREG. TSC2 has been shown to modulate the transcription mediated by members of the steroid receptor superfamily of genes (Henry et al., 1998) and was shown to bind specifically to ERα and inhibit estrogen induced proliferation (Finlay et al., 2004). Also, TSC2 has been shown to possess C-terminal transcriptional activation domains (Tsuchiya et al., 1996). We have therefore attempted to investigate the transcription related functional aspects of TSC2 by exploiting the observed transcriptional repression of EREG. The physiological roles of TSC1 and TSC2 that are independent of the PI3K-AKT-MTOR pathway have been termed as ‘non-canonical’ (Neuman and Henske, 2011). The repression of EREG by TSC2 was observed to be insensitive to rapamycin, suggesting that it was independent of MTORC1 and thus a non-canonical function of TSC2. To determine whether the repression in EREG was at the level of the promoter, we performed a dual luciferase reporter assay. The results showed that the EREG promoter was repressed by stable as well as transient overexpression of TSC2. In order to elucidate the mechanism of transcriptional regulation by TSC2, we performed the ChIP analysis to observe the in vivo binding of TSC2 to the EREG promoter. In the ChIP analysis with the anti-TSC2 antibody, we observed that TSC2 did not bind to the EREG promoter between the regions -857 bp to -302 bp or -325 bp to +165 bp. Further, in silico analysis revealed an interesting trend among the transcription factors that were differentially regulated by TSC2 and had putative binding sites on the EREG promoter. A majority of these transcription factors (17/21) were downregulated by the overexpression of TSC2. This observation suggested that the repression of EREG could be an indirect effect due to repression of transcription factors caused by overexpression of TSC2. On the whole, this study revealed novel functions of TSC2 in OSCC with implications in determining novel biomarkers and therapeutic targets. As discussed previously, OSCC has a very flagitious treatment regime. A prodrug approach is thought to aid in targeting chemotherapy (Rooseboom et al., 2004). CYP1B1, a member of the cytochrome P450 family, has been implicated in chemical carcinogenesis (Bandiera et al., 2005; Sliwinski et al., 2010). There exists a general accordance that this protein is overexpressed in a variety of cancers (e.g., colon, lung, renal, bladder, prostate, breast, endometrial and esophageal cancers), making it an ideal candidate for a prodrug therapy (McFadyen et al., 1999; Murray et al., 2001; McFadyen et al., 2004; Sissung et al., 2006; Wen and Walle, 2007; Sliwinski et al., 2010). The activation of the prodrug facilitated by CYP1B1 would enable the targeting of chemotherapy to tumor tissues in which CYP1B1 is specifically overexpressed as a result reducing the non-specific side effects that the current chemotherapy elicits (Rooseboom et al., 2004). This study was aimed at validating the use of CYP1B1 as a target for the prodrug therapy in OSCC. The expression profile of CYP1B1 was analysed in a panel of 51 OSCC tumors, their corresponding normal tissues, an epithelial dysplasia lesion and its matched normal tissue by qRT-PCR, Western blotting and Immunohistochemistry. Counterintuitively, CYP1B1 was found to be downregulated in 77.78% (28/36) tumor tissues in comparison to their corresponding normal tissues as well as in the epithelial dysplasia lesion compared to its matched normal tissue at the transcriptional level, and in 92.86% (26/28) of tumor tissues at the protein level. This clearly demonstrated the downregulation of CYP1B1 at the transcriptional and translational levels in tumor tissues in comparison to their corresponding normal tissues. These observations indicate that caution should be observed as this therapy may not be applicable universally to all cancers. Since CYP1B1 has been shown to be involved in the activation of pro-carcinogens (Murray et al., 2001; Bandiera et al., 2005; Sissung et al., 2006), its inhibition could facilitate the development of a prophylactic therapy for oral cancer. Overall, this study has identified the transactivation of EGFR as a determinant of sensitivity towards combinatorial targeting of PI3K and MTOR in OSCC and has demonstrated that the autophosphorylation of EGFR (Tyr1173) can be used as a marker to judge the sensitivity towards this treatment. In the clinical perspective, the identification of such markers would aid in predicting the efficacy of targeted therapies. Such investigations would enable the strategic treatment of OSCC patients, thus decreasing the time lost in trial and errors for determining the appropriate treatment. Additionally, this study elucidated a novel role of TSC2 in the transcriptional repression of EREG, a prognostic biomarker for OSCC. Further, the study revealed potential prognostic biomarkers as well as therapeutic targets that are regulated by TSC2 by using a whole genome expression microarray. Moreover, the counterintuitive downregulation of CYP1B1 in OSCC tumors suggested the possibility of a prophylactic therapy for oral cancer but also advised a precautionary note for the application of prodrug treatments based on CYP1B1 overexpression in OSCC.

The thesis analyses the legality of the use of drones in warfare based on the examination of three specific case studies. Firstly the use of armed drones in Afghanistan 2001 and 2002, then Pakistan drone strikes ongoing since 2004 and lastly the Yemen case study. A developed legal framework is used to assess the legality of the use of drones. Furthermore, it briefly touches upon the aspects of morality and ethics of the use of the unmanned aerial vehicles in combat.

No description available.

Deregulated activation of phosphatidylinositol 3-kinase (PI3K) pathway is central to many human malignancies. The functions of this pathway are critical for normal cell metabolism, proliferation, and survival. In lung cancers, the PI3K pathway activity is often aberrantly driven by multiple mutations, including EGFR, KRAS, and PIK3CA. Molecules targeting the PI3K pathway are intensely investigated as potential anti-cancer agents. Although inhibitors of the pathway are currently in clinical trials, rational and targeted use of these compounds, alone or in combination, requires an understanding of isoform-specific activity in context. We sought to identify class IA PI3K enzyme (p110a/PIK3CA, p110b/PIK3CB, p110d/PIK3CD) activities using isoform-specific inhibitors in a lung cancer model system. Treatment of non-small cell lung cancer (NSCLC) cell lines with PIK3CA, PIK3CB, PIK3CD or PIK3CB/D inhibitors resulted in pharmacokinetic and pharmacodynamic responses that frequently tracked with a specific mutation status. Activation of PIK3CA dictated response to the PIK3CA-specific inhibitor while deletion of PTEN phosphatase indicated response to the PIK3CB inhibitor. The PIK3CD isoform-specific inhibitors lacked efficacy in all NSCLC cell lines tested, however treatment at increased concentrations likely provide concurrent inhibition of both PIK3CB/D isoforms improving activity of either agent alone but did not track with a single biomarker. The observed pharmacodynamic and proliferation responses to isoform-specific inhibitors suggested that PI3K isoforms may functionally compensate for loss of another in certain genetic backgrounds. These studies demonstrate unanticipated cellular responses to PI3K isoform inhibition in NSCLC, suggesting that patient populations with specific mutations can benefit from certain isoform-selective inhibitors, or combinations, allowing for rational and targeted clinical use of these agents.

L’objectif de ce mémoire est d’analyser les impacts et l’efficacité de la politique d’assassinats ciblés d’Israël dans le cadre du conflit israélo-palestinien. Pour ce faire, trois angles d’approches sont utilisés; militaire, légale et politique. Pour cette raison, l’hypothèse de départ soutient que la politique compromet la résolution du conflit et se divise en trois sections. Tout d’abord, les assassinats ciblés nuisent au règlement du conflit car ils engendrent un cycle de représailles contre Israël. Deuxièmement, ils représentent une violation du droit international ainsi que du droit national israélien. Finalement, ils sont un sérieux obstacle à la résolution politique du conflit dû au climat de violence et de méfiance qu’ils instaurent. Dans la conclusion, il est retenu que, bien que la politique d’assassinats ciblés ne soit pas efficace pour lutter contre les organisations terroristes, elle n’engendre cependant pas d’effet contreproductif de cycle de violence. Dans un second temps, la politique va à l’encontre de lois internationales mais elle peut cependant être justifiée par certains articles issus de ces mêmes textes alors que la Cour suprême israélienne a reconnu que certaines opérations pouvaient s’avérées légales. Troisièmement, elle nuit bel et bien à la résolution politique du conflit israélopalestinien en exacerbant les tensions de par le climat qu’elle instaure. Finalement, les nombreux impacts de celle-ci sur le conflit n’en font pas une politique efficace. / This goal of this thesis is to analyse the impact and effectiveness of the Israeli targeted killing policy within the context of the Israeli-Palestinian conflict. To this end, three different approaches will be used; military, legal and political. Our hypothesis supports that the policy impedes the resolution to the conflict and is divided into three sections. First of all, Israeli targeted killings impede the conflict resolution because they, in turn, generate retaliations against Israel. Secondly it is a clear violation of international rights, including those of the Israelis. Finally, the policy is a serious obstacle to the settlement of the conflict due to the violent and distrustful atmosphere it arouses. In the conclusion, it is said that, although the policy does not prove to be an effective measure to fight terrorism, neither does it create an escalating cycle of violence. Secondly, the policy is a violation of the international legal system; however it can still be justified by some of the articles present in the same law texts. The Israeli Supreme Court has ruled that some of the operations could be legal. Thirdly, it is effectively detrimental to the resolution of the Israeli-Palestinian conflict because the ambiance it creates exacerbates tensions. In conclusion, the myriad of impacts the policy has on the conflict make it ineffective.